Trung Huynh
Stock Analyst at UBS
(2.36)
# 2,522
Out of 4,896 analysts
46
Total ratings
60%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $560 → $584 | $567.74 | +2.86% | 4 | Jul 11, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $38 → $33 | $3.51 | +840.17% | 2 | May 13, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $22.91 | +65.90% | 2 | May 9, 2025 | |
| INSM Insmed | Maintains: Buy | $110 → $109 | $98.18 | +11.02% | 5 | May 9, 2025 | |
| AMGN Amgen | Maintains: Neutral | $319 → $315 | $295.27 | +6.68% | 4 | May 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,100 → $1,050 | $793.01 | +32.41% | 8 | May 2, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $25.65 | -2.53% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $46.86 | +15.24% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.74 | +302.30% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $4.03 | +222.58% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $156.90 | +11.54% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $83.36 | +51.15% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $192.45 | -11.67% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.73 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Jul 11, 2025
Maintains: Neutral
Price Target: $560 → $584
Current: $567.74
Upside: +2.86%
Jasper Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $3.51
Upside: +840.17%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $22.91
Upside: +65.90%
Insmed
May 9, 2025
Maintains: Buy
Price Target: $110 → $109
Current: $98.18
Upside: +11.02%
Amgen
May 2, 2025
Maintains: Neutral
Price Target: $319 → $315
Current: $295.27
Upside: +6.68%
Eli Lilly and Company
May 2, 2025
Maintains: Buy
Price Target: $1,100 → $1,050
Current: $793.01
Upside: +32.41%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $25.65
Upside: -2.53%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $46.86
Upside: +15.24%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.74
Upside: +302.30%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $4.03
Upside: +222.58%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $156.90
Upside: +11.54%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $83.36
Upside: +51.15%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $192.45
Upside: -11.67%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.73
Upside: -